Tesamorelin vs HGH 191AA

Tesamorelin and HGH 191AA are both research peptides studied across multiple applications, yet they represent distinct pharmacological strategies within the GH axis. Tesamorelin, a synthetic 44-amino-acid GHRH analog, acts upstream by stimulating the pituitary to secrete endogenous GH, thereby preserving feedback regulation. In contrast, HGH 191AA (somatropin) is a 191-amino-acid recombinant protein identical to endogenous GH, providing direct hormone replacement. This mechanistic divergence leads to differences in pharmacokinetics, dosing, and safety profiles. Researchers must weigh these factors when selecting a peptide for studies on body composition, metabolism, or aging. The following sections detail their mechanisms, evidence bases, and practical considerations.

It stimulates endogenous GH and IGF-1 production. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy. by binding to GHRH receptors on the pituitary, mimicking the natural pulsatile release pattern. A newer formulation, Egrifta WR (weekly reconstitution), received FDA approval in March 2025, simplifying dosing. Phase 3 trials demonstrated significant reductions in visceral adipose tissue over 26 weeks, with improvements in skeletal muscle area and density, even in patients on integrase strand transfer inhibitor (INSTI)-based HIV regimens. The evidence base is strongest for HIV-associated lipodystrophy, with limited data in other populations.

HGH 191AA refers to recombinant human growth hormone (somatropin), a 191-amino-acid single-chain polypeptide (MW ~22,124 g/mol) identical in sequence to endogenous pituitary GH. It is FDA-approved for growth hormone deficiency (GHD) in children and adults, Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, and HIV-associated wasting. In the peptide community, '191AA' distinguishes this form from the older 192-amino-acid variant (somatrem), which had an extra methionine and higher immunogenicity. Evidence from randomized controlled trials supports its efficacy in improving lean body mass, reducing fat mass, and increasing bone density in GH-deficient adults. Research in healthy elderly populations suggests potential anti-aging effects, though these applications remain off-label and require careful monitoring for adverse metabolic effects.

Both peptides are studied for body composition, specifically the reduction of adipose tissue and preservation or increase of lean mass. Tesamorelin's research is predominantly focused on HIV-associated lipodystrophy, where it selectively reduces visceral fat without significantly affecting subcutaneous fat. HGH 191AA is studied more broadly, including in GH-deficient adults, aging populations, and conditions like cachexia. Additionally, HGH 191AA is investigated for anti-aging and longevity applications, exploring its effects on skin thickness, muscle strength, and cognitive function in older adults. Tesamorelin has no established research in these areas, limiting its scope to metabolic and HIV-related studies. Researchers should consider the specific population and outcome measures when choosing between the two.

Tesamorelin: Common adverse events include injection site reactions (17%), arthralgia (13%), myalgia (6%), and peripheral edema (6%). Headache, nausea, and flu-like symptoms are also reported. It may increase blood glucose levels, necessitating monitoring in diabetic or prediabetic subjects. Long-term safety data are limited to 26-week trials. HGH 191AA: Common side effects include injection site reactions, fluid retention, joint pain/stiffness, and carpal tunnel syndrome. Metabolic effects are dose-dependent and include insulin resistance and hyperglycemia, which may precipitate diabetes in predisposed individuals. Endocrine effects include gynecomastia and hypothyroidism (due to unmasking of central hypothyroidism). Both peptides require careful dose titration and monitoring, but the direct GH replacement of HGH 191AA carries a higher risk of metabolic disturbances compared to the indirect action of Tesamorelin.